natgillin/translations-raw huggingface dataset:
• medicines used to relax muscles - such as tizanidine 
• zdravila, ki jih uporabljamo za sproščanje mišic - npr. tizanidin,
None of the patients had received prior treatment with a PARP inhibitor. 
Nobena bolnica ni predhodno prejela zdravljenja z zaviralci PARP.
• medicines which suppress the immune system - such as ciclosporin, sirolimus or tacrolimus 
• zdravila za zaviranje imunskega sistema - npr. ciklosporin, sirolimus ali takrolimus,
• medicines to treat allergic reactions - such as astemizole or terfenadine 
• zdravila za zdravljenje alergijskih reakcij - npr. astemizol ali terfenadin,
Patients included in the population PK study were aged 21 to 86 years (58% < 65 years, 31% 65-74 years, and 11% > 75 years), 82% were Caucasian, and had body weights between 41 and 171 kg (73% had body weight > 60 kg). 
Bolnice, ki so bile vključene v študijo populacijske farmakokinetike, so bile stare od 21 do 86 let (58 % < 65 let, 31 % od 65 do 74 let in 11 % > 75 let), 82 % jih je bilo bele rase, njihova telesna teža pa je bila med 41 in 171 kg (73 % jih je imelo telesno težo > 60 kg).
ARIEL3 Efficacy Results Parameter 
Preglednica 4: Rezultati za učinkovitost na podlagi študije ARIEL3
• medicines to treat severe pain - such as alfentanil or fentanyl 
• zdravila za zdravljenje hudih bolečin - npr. alfentanil ali fentanil,
Summary of primary efficacy findings for patients with BRCA-mutant ovarian cancer who received rucaparib 600 mg twice daily and two or more prior chemotherapy regimens based on investigator assessment of response 
Povzetek primarnih ugotovitev o učinkovitosti pri bolnicah z rakom jajčnikov zaradi mutacij gena BRCA, ki so prejemale rukaparib 600 mg dvakrat na dan in so imele v preteklosti dva ali več režimov terapije na podlagi ocene odziva, ki ga oceni raziskovalec Primarna populacija študije učinkovitosti
The median progression-free survival was 162 days (95% CI [51-223]). 
Mediano preživetje brez napredovanja bolezni je bilo 162 dni (95-% IZ [51-223]).
ORR was similar for patients with germline BRCA-mutant ovarian cancer or somatic BRCA-mutant ovarian cancer and for patients with a BRCA1 gene mutation or BRCA2 gene mutation. 
ORR je bil podoben pri bolnicah z rakom jajčnikov zaradi germinalne mutacije BRCA ali somatske mutacije BRCA in pri bolnicah z mutacijo gena BRCA1 ali z mutacijo gena BRCA2.
Supportive care and institutional guidelines should be implemented for the management of low blood counts for the treatment of anaemia and neutropenia. 
Za korigiranje nizkega števila krvnih celic je treba uvesti podporno zdravljenje v skladu s smernicami ustanove za zdravljenje anemije in nevtropenije.
Efficacy of Rubraca as treatment for relapsed or progressive EOC, FTC, or PPC has not been investigated in patients who have received prior treatment with a PARP inhibitor. 
Učinkovitosti zdravila Rubraca pri zdravljenju recidivnega ali napredujočega EOC, FTC ali PPC pri bolnicah, ki so bile pred tem zdravljene z zaviralcem PARP, niso preučili.
There are no clinical data in patients with severe renal impairment (CLcr less than 30 mL/min), therefore rucaparib is not recommended for use in patients with severe renal impairment. 
Kliničnih podatkov pri bolnicah s hudo okvaro ledvic ni (vrednost CLcr nižja od 30 ml/min), zato uporaba rukapariba ni priporočljiva pri bolnicah s hudo okvaro ledvic.
Rubraca has minor influence on the ability to drive and use machines. 
Zdravilo Rubraca ima blag vpliv na sposobnost vožnje in upravljanja strojev.
If you forget to take Rubraca 
Če ste pozabili vzeti zdravilo Rubraca
• medicines used to treat uncontrolled movement or mental disorders - such as pimozide 
• zdravila za zdravljenje nenadzorovanih gibov ali duševnih motenj - npr. pimozid,
Rucaparib also marginally inhibits P-gp in the gut. 
Rukaparib tudi marginalno zavira P-gp v prebavilih.
In patients with cancer, rucaparib had a steady-state volume of distribution of 113 L to 262 L following a single intravenous dose of 12 mg to 40 mg rucaparib. 
Pri bolnicah z rakom je imel volumen porazdelitve rukapariba v stanju dinamičnega ravnovesja od 113 l do 262 l po enkratnem intravenskem odmerku rukapariba od 12 mg do 40 mg.
If you take more tablets than you should, tell your doctor, pharmacist or nurse straight away. 
Če ste vzeli večji odmerek tablet, kot bi smeli, morate takoj obvestiti zdravnika, farmacevta ali medicinsko sestro.
Caution should be used for concomitant use of strong CYP3A4 inhibitors or inducers. 
Pri sočasni uporabi močnih zaviralcev ali induktorjev CYP3A4 je potrebna previdnost.
Median duration of responsea - days (95% CI) 
Mediano trajanje odzivaa - dnevi (95-odstotni IZ)
Because of the potential for serious adverse reactions in breast-fed infants from rucaparib, breast-feeding is contraindicated during treatment with Rubraca and for 2 weeks after the final dose (see section 4.3). 
Zaradi možnih resnih neželenih učinkov rukapariba pri dojenih otrocih je dojenje med zdravljenjem z zdravilom Rubraca in še 2 tedna po zadnjem odmerku kontraindicirano (glejte poglavje 4.3).
Following administration of a single oral dose of [14C]-rucaparib 600 mg to patients, the overall mean recovery of radioactivity was 89.3%, with a mean recovery of 71.9% in faeces and 17.4% in urine by 288 hours post dose. 
Po dajanju enega samega 600 mg peroralnega odmerka [14C]-rukapariba bolnikom je bilo skupno mediano izločanje radioaktivnosti 89,3 %, od tega je mediano izločanje 71,9 % z blatom in 17,4 % z urinom po 288 urah po odmerjanju.
Based on the animal studies, impact on fertility associated with the use of rucaparib cannot be ruled out (see section 5.3). 
Podatkov o učinku rukapariba na plodnost pri človeku ni. Na podlagi študij na živalih učinka na plodnost, povezanega z uporabo rukapariba, ni mogoče izključiti (glejte poglavje 5.3).
In patients ≥ 75 years old, frequencies of some adverse reactions increased: increased blood creatinine (32%), dizziness (20%), pruritus (15%), and memory impairment (4%) were higher than in patients < 75 years old (18%, 15%, 9% and 1% respectively). 
Pri bolnicah, starih ≥ 75 let, so bile pogostnosti nekaterih neželenih učinkov, vključno s povišanjem kreatinina v krvi (32 %), omotico (20 %), pruritusom (15 %) in poslabšanjem spomina (4 %), pogostejše kot pri bolnicah, starih < 75 let (18 %, 15 %, 9 % oziroma 1 %).
In addition, according to its mechanism of action rucaparib may have the potential to impair fertility in humans. 
Poleg tega ima morda rukaparib glede na mehanizem delovanja potencial za škodljive učinke na plodnost pri ljudeh.
• medicines used to cause sleepiness or drowsiness - such as midazolam 
• zdravila, ki jih uporabljamo za povzročanje zaspanosti ali dremavosti - npr. midazolam,
In the subset of 79 platinum-sensitive patients, progression free interval after last platinum dose was ≥ 6 - 12 months for 55 (69.6%) patients and > 12 months for 24 (30.4%) patients. 
V podpopulaciji 79 bolnic z rakom, občutljivim na platino, je interval brez napredovanja bolezni po zadnjem odmerku platine znašal ≥ 6-12 mesecev pri 55 (69,6 %) bolnicah in > 12 mesecev pri 24
HR (95% CI) p-valueb a. All randomised patients. 
Vrednost pb a. Vse randomizirane bolnice.
Rucaparib down regulated CYP2B6 in human hepatocytes at clinically relevant exposures. 
Rukaparib je CYP2B6 pri klinično pomembnih izpostavljenostih v človeških human hepatocitih reguliral navzdol.
Increased ALT was observed in 34.8% (all grades) and 9.9% (≥ CTCAE Grade 3) of patients, increased AST in 31.4% (all grades) and 2.8% (≥ CTCAE Grade 3) of patients and increased ALT and AST in 28.6% (all grades) and 2.1% (≥ CTCAE Grade 3) of patients. 
Zvišanje ALT so opažali pri 34,8 % (vse stopnje) in 9,9 % (≥ stopnja CTCAE 3) bolnic, zvišanje AST pri 31,4 % (vse stopnje) in 2,8 % (≥ stopnja CTCAE 3) bolnic, zvišanje ALT in AST pa pri 28,6 % (vse stopnje) in 2,1 % (≥ stopnja CTCAE 3) bolnic.
CYP1A2 substrates 
Substrati CYP1A2
Increased blood creatinine, Hypercholesterolaemiab 
Občasni zvišane ravni kreatinina v krvi, hiperholesterolemijab
Fatiguec, Pyrexia 
Zelo pogosti utrujenostc, pireksija
In a population PK analysis, no clinically relevant PK differences were observed among patients with different CYP2D6 phenotypes (including poor metabolizers, n=9; intermediate metabolizers, n=71; normal metabolizers, n=76; and ultra-rapid metabolizers, n=4) or patients with different CYP1A2 phenotypes (including normal metabolizers, n=28; hyperinducers, n=136). 
V analizi populacijske farmakokinetike niso opazili razlik med bolnicami z različnimi fenotipi CYP2D6 (vključno s slabimi presnavljalkami, n = 9; srednjimi presnavljalkami, n = 71; normalnimi presnavljalkami, n = 76 in ultrahitrimi presnavljalkami, n = 4) ali med bolnicami z različnimi fenotipi CYP1A2 ( vključno z normalnimi presnavljalkami, n = 28; hiperinduktorji, n = 136).
• medicines to lower blood sugar levels and treat diabetes - such as metformin 
• zdravila za zniževanje ravni sladkorja v krvi in za zdravljenje sladkorne bolezni - npr.
Increased rucaparib-induced cytotoxicity and anti-tumour activity was observed in tumour cell lines with deficiencies in BRCA1/2 and other DNA repair genes. 
V tumorskih celičnih linijah so opazili povečano citotoksičnost in protitumorsko delovanje ter pomanjkanje BRCA1/2 in drugih genov za popravilo DNK.
Caution is advised when co-administering medicinal products that are CYP3A substrates with a narrow therapeutic index (e.g., alfentanil, astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, terfenadine). 
Ob sočasnem dajanju zdravil, ki so substrati CYP3A z ozkim terapevtskim indeksom (npr. alfentanil, astemizol, cisaprid, ciklosporin, dihidroergotamin, ergotamin, fentanil, pimozid, kinidin, sirolimus, takrolimus, terfenadin) je potrebna previdnost.
In a medicinal product interaction study in cancer patients, the effects of steady-state rucaparib at 600 mg twice daily on CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp were evaluated with single oral doses of sensitive probes (caffeine, S-warfarin, omeprazole, midazolam, and digoxin, respectively). 
V študiji medsebojnega delovanj zdravil, v kateri so sodelovale bolnice z rakom, so ocenjevali učinke rukapariba v stanju dinamičnega ravnovesja ob odmerku 600 mg, dvakrat na dan, na CYP1A2, CYP2C9, CYP2C19, CYP3A in P-gp z enkratnimi peroralnimi odmerki občutljivih substratov (kofein, S-varfarin, omeprazol, midazolam in digoksin).
In vitro, rucaparib is an inhibitor of the BCRP and P-gp efflux transporters. 
In vitro je rukaparib zaviralec BCRP in efluksnih prenašalcev Pgp.
Rubraca is supplied in plastic bottles. 
Zdravilo Rubraca je na voljo v plastenkah.
Women of reproductive potential should be advised to use effective contraception during treatment and for 6 months following the last dose of Rubraca (see section 4.6). 
Ženskam v rodni dobi je treba svetovati, naj med zdravljenjem in še 6 mesecev po zadnjem odmerku zdravila Rubraca uporabljajo učinkovito kontracepcijo (glejte poglavje 4.6).
Carcinogenicity studies have not been performed with rucaparib. 
Študij karcinogenosti z rukaparibom niso opravili.
When co-administering medicinal products metabolized by CYP1A2, particularly medicines which have a narrow therapeutic index (e.g., tizanidine, theophylline), dose adjustments may be considered based on appropriate clinical monitoring. 
Ob sočasnem dajanju zdravil, ki se presnavljajo prek izoencima CYP1A2, še zlasti zdravil z ozkim terapevtskim indeksom (npr. tizanidin, teofilin), bo morda treba razmisliti o prilagoditvi odmerkov na podlagi ustreznega kliničnega spremljanja.
Dose adjustments for adverse reactions 
Prilagoditve odmerka zaradi neželenih učinkov
There are limited clinical data in patients with moderate or severe hepatic impairment (ie, any total bilirubin greater than 1.5 times ULN), therefore rucaparib is not recommended for use in patients with moderate or severe hepatic impairment. 
Klinični podatki pri bolnicah z zmerno ali hudo okvaro jeter (tj. vsakršna skupna vrednost bilirubina, večja od 1,5-kratne vrednosti ULN) so omejeni, zato uporaba rukapariba ni priporočljiva pri bolnicah z zmerno ali hudo okvaro jeter.
Before taking Rubraca as treatment for relapsed or progressive EOC, FTC, or PPC, patients must have confirmation of deleterious germline or somatic mutations in the breast cancer 1 (BRCA1) or breast cancer 2 (BRCA2) gene using a validated test. 
Pred začetkom jemanja zdravila Rubraca pri zdravljenju recidivnega ali napredovalega EOC, FTC ali PPC je treba pri bolnicah potrditi škodljive germinalne ali somatske mutacije gena dovzetnosti za raka dojk 1 (BRCA1) ali gena dovzetnosti za raka dojk 2 (BRCA2) z validirano testno metodo.
A population PK analysis was performed to evaluate the effect of renal impairment on the clearance of rucaparib in patients receiving rucaparib 600 mg twice daily. 
Populacijska farmakokinetična analiza je bila opravljena z namenom ocene učinka okvare jeter na očistek rukapariba pri bolnicah, ki so prejemale rukaparib v odmerku 600 mg dvakrat na dan.
Caution when driving or using machines is advised for patients who report fatigue, nausea, or dizziness during treatment with Rubraca (see section 4.8). 
Bolnice, ki med zdravljenjem z zdravilom Rubraca poročajo o utrujenosti, navzei ali omotici, morajo biti previdne pri vožnji in upravljanju strojev (glejte poglavje 4.8).
Inhibition of MRP4 by rucaparib cannot be fully ruled out at clinical exposures. 
Zaviranja MRP4 s strani rukapariba pri kliničnih izpostavljenostih ni mogoče v celoti izključiti.
Rucaparib is a weak inhibitor of CYP2C8, CYP2D6, and UGT1A1. 
Rukaparib je šibek zaviralec CYP2C8, CYP2D6 in UGT1A1.
In vitro, rucaparib was shown to be a substrate of P-gp and BCRP, but not a substrate of renal uptake transporters OAT1, OAT3, and OCT2, or hepatic transporters OAPT1B1 and OATP1B3. 
Podatki in vitro so pokazali, da je rukaparib substrat P-gp in BCRP, ni pa substrat ledvičnih privzemnih prenašalcev OAT1, OAT3 in OCT2 ali jetrnih prenašalcev OAPT1B1 in OATP1B3.
PAES: In order to further investigate the efficacy of rucaparib maintenance treatment in patients with relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy, the MAH should submit the final analysis of OS and updated analyses of PFS2, chemotherapy-free interval and time to start of subsequent anti-cancer treatment of the phase 3, randomised, double-blind study CO-338-014 
PAES: Za nadaljnje raziskovanje učinkovitosti vzdrževalnega zdravljenja z rukaparibom pri bolnicah z recidivnim epitelijskim rakom jajčnikov, jajcevodov ali primarnim peritonealnim rakom visoke stopnje, ki se (v celoti ali delno) odzivajo na kemoterapijo s platino, bo imetnik dovoljenja za promet predložil končno analizo OS in posodobljene analize PFS2, intervala brez kemoterapije in časa do začetka nadaljnjega zdravljenja raka iz randomizirane dvojno slepe študije 3. faze CO-338-014.
The clinical relevance of UGT1A1 inhibition by rucaparib is not clear. 
UGT1A1 s strani rukapariba ni jasen.
d. tBRCA includes all patients with a deleterious germline or somatic BRCA mutation, as determined by the CTA. 
d. tBRCA vključuje vse bolnice s škodljivo zarodno linijo celic ali somatsko mutacijo BRCA, ugotovljeno s kliničnim preskušanjem.
Rubraca may affect your ability to drive or use tools or machines. 
Zdravilo Rubraca lahko vpliva na vašo sposobnost upravljanja vozil in strojev.
At the predicted median steady-state Cmax following 600 mg rucaparib twice daily, the projected QTcF increase from baseline was 11.5 msec (90% CI: 8.77 to 14.2 msec). 
Ob pričakovanem medianem Cmax v stanju dinamičnega ravnovesja po dajanju rukapariba v odmerku 600 mg dvakrat na dan je predvideno podaljšanje intervala QTcF od izhodišča znašalo 11,5 msec (90-odstotni IZ: 8,77 do 14,2 msec).
Rucaparib showed no effect on Cmax of caffeine while moderately increasing AUCinf of caffeine by 2.55 fold (90% CI: 2.12, 3.08). 
Rukaparib ni kazal nikakršnega učinka na Cmax kofeina, je pa zmerno povišal AUCinf kofeina za 2,55-krat (90-odstotni IZ: 2,12, 3,08).
The tumour histology was high grade serous in 91.5% of patients, endometrioid in 2.8% and mixed histology in 4.7%. 
Histologija tumorja je bila pri 91,5 % bolnic serozni karcinom visoke stopnje, pri 2,8 % endometrioidni karcinom, pri 4,7 % bolnic pa je bila histologija mešana.
The efficacy of rucaparib was investigated in ARIEL3, a double-blind, multicentre clinical trial in which 564 patients with recurrent EOC, FTC or PPC who were in response to platinum-based chemotherapy were randomized (2:1) to receive Rubraca tablets 600 mg orally twice daily (n=375) or placebo (n=189). 
Vzdrževalno zdravljenje recidivnega raka jajčnikov Učinkovitost rukapariba so raziskovali v dvojno slepem, multicentričnem kliničnem preskušanju ARIEL3, v katerem je sodelovalo 564 bolnic s ponavljajočimi se EOC, FTC ali PPC in z odzivnostjo na kemoterapijo na osnovi platine, randomiziranih (2 : 1) za prejemanje tablet zdravila Rubraca 600 mg peroralno dvakrat na dan (n = 375) oziroma placeba (n = 189).
HR (95% CI) p-valueb 
HR (95-% IZ) Vrednost pb
Potential in vivo BCRP inhibition cannot be excluded. 
Potenciala za in vivo zaviranje BCRP ni mogoče izključiti.
No studies have been conducted to investigate the pharmacokinetics of rucaparib in paediatric patients. 
Študije za preučevanje farmakokinetike rukapariba pri pediatričnih bolnikih niso bile opravljene.
Adverse reactions that most commonly led to dose reduction or interruption were anaemia (20%), fatigue/asthenia (18%), nausea (16%), thrombocytopenia (15%), and AST/ALT elevations (10%). 
Neželeni učinki, ki so najpogosteje vodili do zmanjšanja odmerka ali prekinitve zdravljenja, so bili anemija (20 %), utrujenost/astenija (18 %), navzea (16 %), trombocitopenija (15 %) in zvišanje ravni ALT/AST (10 %).
If a patient vomits after taking Rubraca, the patient should not retake the dose and should take the next scheduled dose. 
Če bolnica po zaužitju zdravila Rubraca bruha, ne sme znova vzeti odmerka, pač pa vzame šele naslednji načrtovani odmerek.
Rucaparib induced structural chromosomal aberrations in the in vitro human lymphocyte chromosomal aberration assay. 
Rukaparib je povzročil strukturne kromosomske aberacije in vitro testu kromosomskih aberacij v človeških levkocitih.
• medicines to treat stomach problems - such as cisapride, omeprazole 
• zdravila za zdravljenje težav z želodcem - npr. cisaprid, omeprazol,
There are no or limited data from the use of rucaparib in pregnant women. 
O uporabi rukapariba pri nosečnicah ni podatkov oziroma so ti omejeni.
Increased transaminases 
Pogosti zvišane ravni transaminazb
• anticonvulsant medicines used to treat fits (seizures) and epilepsy - such as phenytoin 
• zdravila, ki jih uporabljamo za zdravljenje napadov krčev (epileptičnih napadov) in epilepsije (antikonvulzivi) - npr. fenitoin,
UNIQUE IDENTIFIER - 2D BARCODE UNIQUE IDENTIFIER - HUMAN READABLE DATA 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA EDINSTVENA OZNAKA - V BERLJIVI OBLIKI
Decreased appetite, Increased blood creatinineb 
Zelo pogosti zmanjšan apetit, zvišane ravni kreatinina v krvib
• being short of breath, feeling tired, having pale skin, or fast heart beat - these may be signs of a low red blood cell count (anaemia) 
- kratka sapa, občutek hude utrujenosti, bledica kože ali hitro bitje srca - to so lahko znaki nizkega števila rdečih krvnih celic (anemije), - podplutbe ali krvavitve, ki trajajo dlje kot po navadi, če se poškodujete - to so lahko znaki nizkega števila krvnih ploščic (trombocitopenije), - vročina ali okužba - to sta lahko znaka nizkega števila belih krvnih celic (nevtropenije);
The primary efficacy outcome was investigator-assessed progression-free survival (invPFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (v1.1). 
Response Evaluation Criteria in Solid Tumors), različica 1.1 (v1.1).
When co-administering medicinal products that are CYP2C9 substrates with a narrow therapeutic index (e.g., warfarin, phenytoin), dose adjustments may be considered, if clinically indicated. 
Ob sočasnem dajanju zdravil, ki so substrati CYP2C9 z ozkim terapevtskim indeksom (npr. varfarin, fenitoin), bo morda treba razmisliti o prilagoditvi odmerkov, če bo to klinično indicirano.
What Rubraca looks like and contents of the pack 
Izgled zdravila Rubraca in vsebina pakiranja
If you are not sure, talk to your doctor, pharmacist or nurse before taking Rubraca. 
Če ste negotovi, se pred začetkom jemanja zdravila Rubraca posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
• Tablet content: Microcrystalline cellulose, sodium starch glycolate (Type A), colloidal anhydrous silica and magnesium stearate. 
• Vsebina tablete: Mikrokristalna celuloza, natrijev karboksimetilškrob (vrsta A), brezvodni koloidni silicijev dioksid in magnezijev stearat
The most abundant metabolite was M324, an oxidative deamination product of rucaparib, accounting for 18.6% of the radioactivity in plasma. 
Največ je bilo presnovka M324, ki je produkt oksidativne deaminacije rukapariba in ki je v plazmi predstavljal
No clinically important differences were observed between 34 patients with mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN or total bilirubin > 1.0 to 1.5 times ULN and any AST) and 337 patients with normal hepatic function. 
Med 34 bolnicami z blago okvaro jeter (skupni bilirubin ≤ ULN in AST > ULN ali skupni bilirubin > 1,0- do 1,5-kratnik ULN in kakršna koli AST) in 337 bolnicami z normalnim delovanjem jeter niso opazili nobenih klinično pomembnih razlik.
Rucaparib showed no effect on Cmax of digoxin while marginally increasing AUC0-72h by 1.20 fold (90% CI: 1.12 to 1.29). 
Rukaparib ni pokazal nikakršnega učinka na Cmax digoksina in je marginalno povišal AUC0-72 h za 1,20-krat (90-odstotni IZ: 1,12 do 1,29).
Contents of the pack and other information 
Shranjevanje zdravila Rubraca Vsebina pakiranja in dodatne informacije
In vitro, rucaparib reversibly inhibited CYP1A2, CYP2C19, CYP2C9, and CYP3A, and to a lesser extent CYP2C8, CYP2D6, and UGT1A1. 
In vitro je rukaparib povratno zaviral CYP1A2, CYP2C19, CYP2C9 in CYP3A, v manjši meri pa tudi CYP2C8, CYP2D6 in UGT1A1.
• Rubraca is available as either 200 mg, 250 mg or 300 mg tablets. 
- Zdravilo Rubraca je na voljo v obliki 200-miligramskih, 250-miligramskih ali 300-miligramskih tablet.
The ≥ Grade 3 adverse reactions occurring in > 5% of patients were anaemia (23%), ALT elevations (10%), fatigue/asthenia (10%), neutropenia (8%), thrombocytopenia (6%), and nausea (5%). 
Neželeni učinki stopnje ≥ 3, ki so se pojavili pri > 5 % bolnic, so bili anemija (23 %), zvišanje ravni ALT (10 %), utrujenost/astenija (10 %), nevtropenija (8 %), trombocitopenija (6 %) in navzea (5 %).
Patients should avoid spending time in direct sunlight because they may burn more easily during rucaparib treatment; when outdoors, patients should wear a hat and protective clothing, and use sunscreen and lip balm with sun protection factor (SPF) of 50 or greater. 
Ko so zunaj, naj bolnice nosijo klobuk in zaščitna oblačila, uporabljajo naj preparate za zaščito pred soncem in balzam za ustnice z zaščitnim faktorjem (SPF) 50 ali več.
b Includes laboratory findings c Includes fatigue, asthenia and lethargy 
c Vključuje utrujenost, astenijo in letargijo.
Microcrystalline cellulose Sodium starch glycolate (Type A) Colloidal anhydrous silica Magnesium stearate 
Jedro tablete mikrokristalna celuloza natrijev karboksimetilškrob (vrsta A) brezvodni koloidni silicijev dioksid magnezijev stearat
The in vitro protein binding of rucaparib is 70.2% in human plasma at therapeutic concentration levels. 
Vezava rukapariba v človeški plazmi v območju terapevtskih koncentracij in vitro je 70,2 %.